Drug Search Results
More Filters [+]

Nastorazepide

Alternative Names: nastorazepide, z-360
Latest Update: 2022-07-12
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CCK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Zeria Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nastorazepide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Pancreatic Cancer|Adenocarcinoma

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ZIPANG

P2

Completed

Pancreatic Cancer|Adenocarcinoma

2016-07-01

01A10101

P1

Completed

Healthy Volunteers

2013-04-01

01010106E

P2

Completed

Pancreatic Cancer

2007-12-01

2005-001659-39

P2

Completed

Pancreatic Cancer

2007-02-07

Recent News Events